Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2003-2008

  Liu, Kai ^a   Song, Xilin ^a   Zhu, Meirong ^b   Ma, Heng ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Fibroblast growth factor receptor 2; Gastric cancer; MET; Resistance

Indexed keywords

3 (2,6 DICHLORO 3,5 DIMETHOXYPHENYL) 1 [6 [[4 (4 ETHYL 1 PIPERAZINYL) PHENYL] AMINO] 4 PYRIMIDINYL] 1 METHYLUREA; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; GENE; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84940021977     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3601     Document Type: Article

References (23)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, et al: Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut 60: 1644-1649, 2011.
3. Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N, et al: Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol 17: 3390-3397, 2011.
4. Meyer HJ and Wilke H: Treatment strategies in gastric cancer. Dtsch Arztebl Int 108: 698-705, 2011.
5. Morishita A, Gong J and Masaki T: Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 20: 4536-4545, 2014.
6. Maestrini E, Tamagnone L, Longati P, Cremona O, Gulisano M, Bione S, et al: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA 93: 674-678, 1996.
7. Sattler M and Salgia R: c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. Curr Oncol Rep 9: 102-108, 2007.
8. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953, 2000.
9. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
10. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K and Nakanishi I: Amplification of c-myc, K-sam and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78: 1143-1153, 1998.
11. Sierra JR and Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3 (Suppl): S21-S35, 2011.
12. Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, et al: MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 4: 9-17, 2013.
13. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: 3314-3322, 2007.
14. Abidoye O, Murukurthy N and Salgia R: Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials 2: 143-147, 2007.
15. Bengtsson H, Irizarry R, Carvalho B and Speed TP: Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 24: 759-767, 2008.
16. Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, et al: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One 9: e92147, 2014.
17. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
18. Oshima T and Masuda M: Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today 42: 313-327, 2012.
19. Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, et al: Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs 31: 1158-1168, 2013.
20. Jänne PA, Gray N and Settleman J: Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723, 2009.
21. Sebolt-Leopold JS and English JM: Mechanisms of drug inhibition of signalling molecules. Nature 441: 457-462, 2006.
22. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, et al: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9: 121, 2010.
23. Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, et al: A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though [corrected] MAPK activation. PLoS One 7: e39653, 2012.